Mitochondrial & cellular energy research
SS-31 / Elamipretide
Established or regulatory evidenceElamipretide, also called SS-31, interacts with a lipid in mitochondrial membranes. A specific pharmaceutical product has an FDA-approved use in Barth syndrome. That narrow approval does not validate general anti-aging or energy claims.
Source review: September 9, 2026. Scientific evidence and trial records change over time.
01 · What is it?
The identity comes first.
Elamipretide, also called SS-31, interacts with a lipid in mitochondrial membranes. A specific pharmaceutical product has an FDA-approved use in Barth syndrome. That narrow approval does not validate general anti-aging or energy claims.
Scientific classification: Mitochondria-targeted synthetic tetrapeptide
For example. It is studied more like an interaction with the lining of an energy plant than a key turning a surface receptor.
02 · How does it work?
The signal, explained.
It interacts with a special fat-like molecule in the inner mitochondrial membrane. Researchers study whether that interaction changes the organization and performance of the cell’s energy-producing machinery.
The key research focus is Mitochondrial cardiolipin. A target describes where an interaction may occur; it does not by itself establish a benefit.
Learn the Science · mechanism
Elamipretide binds cardiolipin, a phospholipid enriched in the inner mitochondrial membrane. Cardiolipin organization is important for respiratory-chain function and mitochondrial membrane architecture.
03 · What happens after the signal?
Follow the downstream effects.
Research examines electron transfer, ATP generation and oxidative stress following membrane interactions. These molecular observations do not establish universal improvement in cellular energy.
To connect this mechanism to a real-world outcome, researchers need to establish exposure at the target, measure the response and test whether the change matters in a controlled human study.
04 · What is it commonly researched for?
The questions researchers are asking.
Researchers have investigated mitochondrial dysfunction, including Barth syndrome and other disease-specific populations.
These are areas of investigation, not promises about a Maison product.
05 · Body systems involved
Where the biology connects.
- Mitochondria
- Cellular organelles involved in energy conversion and metabolic signaling, rather than a separate organ.
- Skeletal muscle
- Relevant to energy use, mitochondrial activity or tissue-model endpoints.
- Cardiovascular system
- Relevant to vascular, cardiac or metabolic outcomes only within the research described.
06 · Receptor / target profile
The molecular reference card.
- Primary receptor or target
- Mitochondrial cardiolipin
- Secondary interactions
- No additional primary target established for the research claim discussed.
- Where it is found
- Inner mitochondrial membrane, particularly cardiolipin-rich regions.
- Activation, inhibition or interaction
- Elamipretide binds cardiolipin, a phospholipid enriched in the inner mitochondrial membrane. Cardiolipin organization is important for respiratory-chain function and mitochondrial membrane architecture.
- Important downstream pathways
- Research examines electron transfer, ATP generation and oxidative stress following membrane interactions. These molecular observations do not establish universal improvement in cellular energy.
07 · Evidence quality
What carries weight—and what does not.
STRONGER EVIDENCE
Forzinity received accelerated FDA approval in 2025 for muscle strength in Barth syndrome in patients weighing at least 30 kg.
EMERGING HUMAN EVIDENCE
The initial randomized study did not meet its primary endpoints. Strength changes in an open-label extension informed accelerated approval; confirmatory evidence remains important.
EARLY / PRECLINICAL EVIDENCE
The mechanistic observations described above do not establish the same outcomes in people.
UNKNOWN OR NOT WELL ESTABLISHED
Long-term outcomes, comparative benefit, clinically meaningful effects and safety for broad wellness use are not well established.
A familiar mechanism, a patent, a testimonial or a trial registration alone cannot establish human efficacy or product quality.
08 · Who is studying it?
Follow the original research.
Stealth BioTherapeutics (approved product development)
Regulatory context: A specific elamipretide medicine has accelerated FDA approval. Research SS-31 products are not that approved medicine, and broader longevity uses are not established.
VIEW CURRENT CLINICAL TRIALSRegistry links may include related compounds or historical studies. Read the exact intervention, sponsor, phase and latest update date. Recruitment status is specific to each trial.
09 · Research terminology
A small glossary for this page.
Target
The molecule or biological structure a compound interacts with.
Pathway
A sequence of cellular events connecting a signal to a response.
Preclinical
Research outside human clinical trials, including cells and animals.
ATP
A molecule cells use to transfer usable chemical energy.
cardiolipin
A lipid concentrated in the inner mitochondrial membrane that helps organize energy-producing machinery.
oxidative stress
A disruption in redox balance that can damage molecules; reactive oxygen species also have normal signaling roles.
Biomarker
A measurable biological feature. A change in a marker does not always translate into a meaningful health outcome.
Target engagement
Evidence that a compound actually reaches and interacts with the intended biological target.
Randomized controlled trial
A study that assigns participants by chance to comparison groups, helping separate an intervention’s effects from other influences.
10 · Research status & limitations
Keep the boundaries visible.
A specific elamipretide medicine has accelerated FDA approval. Research SS-31 products are not that approved medicine, and broader longevity uses are not established.
Long-term outcomes, comparative benefit, clinically meaningful effects and safety for broad wellness use are not well established.
The main evidence category here is established or regulatory evidence. The exact molecule, formulation, study population and endpoint matter. Scientific evidence changes; this page is a dated educational summary, not continuous trial monitoring.
11 · References / continue reading
Go to the source.
- FDA · Forzinity approval and evidence limitations
- FDA · approved product scientific label
- FDA · Forzinity accelerated approval (checked October 9, 2026)
Individual study links support the associated research discussion. Literature-search links are clearly labelled and help you explore further; they are not themselves proof of a claim. Sponsor announcements should be read alongside published papers and current regulatory records.